Healthcare Industry News:  Fragile X 

Biopharmaceuticals Neurology Personnel

 News Release - June 21, 2016

Neurotrope Appoints Paula T. Trzepacz, M.D. as Executive Vice President and Chief Medical Officer

NEWARK, N.J., June 21, 2016 -- (Healthcare Sales & Marketing Network) -- Neurotrope, Inc. (NTRP): today announced that Paula T. Trzepacz, M.D., has joined Neurotrope BioScience, Inc., the Company's wholly owned operating subsidiary, as its Executive Vice President and Chief Medical Officer.

Prior to joining Neurotrope, Dr. Trzepacz was at Eli Lilly and Company for over 15 years where she was most recently a Senior Medical Fellow in Neurosciences drug development. She served on the global drug development team for Amyvid, the PET radiotracer indicated for estimation of beta-amyloid plaque density in brains of cognitively impaired persons suspected of having Alzheimer's disease. Prior to that, she led the Phase 2 medical team investigating mibampator, a novel AMPA receptor potentiator, for agitation and aggression in Alzheimer's disease patients. As Senior Medical Fellow on the global Strattera team for over three years Dr. Trzepacz was the medical lead for registration and regulatory related issues for its Attention Deficit Hyperactivity Disorder indications for both adult and pediatric populations, including design of new Phase 3 registration trials and collaborations with the European and Japanese Lilly teams. As Senior Medical Director of U.S. Neurosciences, she was responsible for a large medical team of physicians and other scientists including for the design and execution of many Phase 4 double-blind, randomized placebo-controlled clinical trials over a five year period. Some of those trials were used to support registration work in addition to answering key patient-relevant questions for practicing physicians. Importantly, the products her team supported included Prozac, Zyprexa, Cymbalta, and Strattera and their multiple indications, line extensions, and formulations.

Dr. Trzepacz is a geriatric psychiatrist and neuropsychiatrist. She is currently Clinical Professor of Psychiatry at Indiana University School of Medicine where she has served since 2004. In the past Dr. Trzepacz was Associate Professor of Psychiatry and Neurology at the University of Pittsburgh School of Medicine and Professor of Psychiatry and Neurology at the University of Mississippi Medical School, where she directed clinical services and participated in NIH-funded research. She served as President of the American Neuropsychiatric Association in 2009-2011 and of the Academy of Psychosomatic Medicine in 2004-2005. Dr. Trzepacz serves on four journal editorial boards, most recently joining "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring." Dr. Trzepacz earned her B.A. at Wellesley College and M.D. at Geisel School of Medicine at Dartmouth College. After a year of Internal Medicine residency she completed a Psychiatry residency and Consultation-Liaison Psychiatry Fellowship at Dartmouth.

"We are pleased to welcome Paula to the Neurotrope team as our Chief Medical Officer," said Charles S. Ramat, President and Chief Executive Officer of Neurotrope. "Paula has a demonstrated track record of success in leading clinical development efforts in multiple therapeutic areas, most importantly Alzheimer's disease and other neurological disorders in adult and pediatric populations and has a strong academic medicine background. This broad clinical research expertise will be invaluable to Neurotrope as we continue advancing and expanding our pipeline of Bryostatin and Bryologs."

About Neurotrope

Neurotrope BioScience, Inc., a wholly owned subsidiary of Neurotrope, Inc., is at the forefront of biotechnology companies having a focus on developing a novel therapy for the treatment of moderately severe to severe Alzheimer's disease. The scientific basis of our treatment is activation of Protein Kinase C isozymes e and a by bryostatin, a natural product, which can result in repair of damaged synapses as well as synaptogenesis, reduction of toxic amyloid generation, and enhancement of memory and learning, thus having the potential to improve cognition and behavior in Alzheimer's disease.

Neurotrope is also conducting preclinical studies of bryostatin as a treatment for Fragile X Syndrome and Niemann-Pick Type C disease, two rare genetic diseases for which only symptomatic treatments are currently available. The Food and Drug Administration has granted Orphan Drug Designation to Neurotrope for bryostatin as a treatment for Fragile X Syndrome. Bryostatin has undergone testing in over 1400 people establishing a large safety database.

Neurotrope has exclusively licensed technology from the Blanchette Rockefeller Neurosciences Institute for Alzheimer's disease and Fragile X Syndrome, has a world-wide, exclusive license with the Icahn School of Medicine at Mt. Sinai for Niemann-Pick Type C. The company has also entered into a collaboration with and is partnered with Stanford University to synthesize and find the next generation bryostatin called bryologs.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the proposed study and timing of initiation, and continued development of use of bryostatin for Alzheimer's disease and other cognitive diseases, and the Company's ability to list its common shares on a major stock exchange. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company's patent portfolio, the Company's inability to expand the Company's business, the Company's inability to meet listing requirements for major stock exchanges, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company's raw materials, existing or increased competition, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended December 31, 2015and Quarterly Report on Form 10-Q for the quarter ended March 31, 2016. The Company does not undertake to update these forward-looking statements.

Please visit for further information.

Source: Neurotrope

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.